TAS-205, targeting hematopoietic prostaglandin D synthase, showed no significant efficacy in improving time to rise in DMD patients over 52 weeks. The REACH-DMD trial was a placebo-controlled, ...
TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results